Newron Pharmaceuticals Advances Evenamide Trials, Reports Mixed 2025 Financials — Newron Pharmaceuticals S.p.A.

Event summary

Newron reported a net loss of EUR 13.2 million in 2025, down from a net profit of EUR 15.8 million in 2024 due to lower license income.
The company initiated pivotal Phase III ENIGMA-TRS clinical trials for evenamide in treatment-resistant schizophrenia (TRS).
Newron secured EUR 38 million in new funding through a share subscription agreement in February 2026.
The European Patent Office granted an additional patent for evenamide, extending its exclusivity until 2044.
Newron plans to propose two new independent non-executive Board members and potentially list shares on a US stock exchange.

The big picture

Newron's strategic focus on evenamide as a potential blockbuster treatment for treatment-resistant schizophrenia is advancing, but the company faces financial challenges. The biopharmaceutical sector is increasingly competitive, and Newron's ability to secure additional funding and successfully navigate regulatory hurdles will be critical. The company's efforts to extend patent exclusivity and explore new markets underscore its long-term strategic vision.

What we're watching

Clinical Trial Progress: The pace at which Newron completes its Phase III ENIGMA-TRS trials will determine the timeline for potential regulatory approval of evenamide.
Financial Sustainability: Whether Newron's EUR 38 million funding round and extended cash runway will be sufficient to support operations through 2027.
Strategic Partnerships: How Newron's potential US listing and additional global development opportunities for evenamide will impact its market position.